Eurofins Scientific stock reaches 4-year high at €76.34
Eurofins Scientific posted an unprecedented peak this Thursday at €76.34, ranking among the strongest gainers in the CAC 40 mid-morning. The stock's bullish momentum is accelerating in a context of a slightly positive Paris index, with the CAC 40 gaining 0.26% during the session.
A four-year record breached as all three moving averages are substantially exceeded
The Eurofins Scientific stock touched €76.34 during the session, up 2.17% compared to the previous close at €74.70. Intraday, the Luxembourg-based group reached €76.34, surpassing the previous peak of €76.30 established in 2022, a year marked by the sharp rise in rates and the war in Ukraine. This is a four-year high that the stock has just broken through. The progression is solid across different timeframes: the stock is up 7.58% over seven days and 8.35% over one month, after having already breached its resistance at €74.08 during the previous session.
Technical configuration confirms this momentum. The price is trading well above its three moving averages: the 20-day MA at €72.34 (spread of +5.50%), the 50-day MA at €70.39 (spread of +8.42%), and the 200-day MA at €65.90 (spread of +15.81%). The RSI at 66, in the upper zone but without signaling extreme overbought conditions, reflects a structured bullish trend. The next prospective reference point is located at the psychological level of €80.00, a round threshold above the current price, with no identified technical resistance in between.
Profitability nearly in line with 2027 target and an acquisition expected by year-end
On the fundamental side, the half-year results published on July 23, 2026 had set the tone: management indicated at that time that the group's profitability was "nearly in line with the 2027 target, with more than a year to spare." The reduction in cutting-edge investments contributed to a marked increase in cash generation, according to H1 2026 communications. Among the points of caution raised on that occasion, organic revenue growth had not yet returned to its usual pace, although the trend was improving as the semester progressed, and the ancillary bioPharma activities remained weak in North America.
Regarding prospects, the group anticipated a rebound in these activities in the second half of 2026, and the acquisition of Element Materials Technology in North America, adding over $150 million in annual revenues in life sciences testing services, was expected to be finalized in the fourth quarter of 2026. The performance of +21.68% over three months illustrates the extent of the stock market revaluation since summer.
